1. Home
  2. YJ vs XCUR Comparison

YJ vs XCUR Comparison

Compare YJ & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yunji Inc. American Depository Shares

YJ

Yunji Inc. American Depository Shares

HOLD

Current Price

$1.85

Market Cap

13.3M

ML Signal

HOLD

XCUR

Exicure Inc.

N/A

Current Price

$1.37

Market Cap

13.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
YJ
XCUR
Founded
2015
2011
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.3M
13.7M
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
YJ
XCUR
Price
$1.85
$1.37
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.6M
63.4K
Earning Date
03-27-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
83.37
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.11
$1.18
52 Week High
$13.97
$9.48

Technical Indicators

Market Signals
Indicator
YJ
XCUR
Relative Strength Index (RSI) 52.79 32.68
Support Level $1.38 N/A
Resistance Level $13.97 $2.02
Average True Range (ATR) 1.20 0.13
MACD 0.03 0.00
Stochastic Oscillator 5.59 20.63

Price Performance

Historical Comparison
YJ
XCUR

About YJ Yunji Inc. American Depository Shares

Yunji Inc is a social e-commerce platform in China using a membership-based model that leverages the power of social interaction. The group offers high-quality products at attractive prices and incentivizes members to promote its platform and share products with their social contacts. It empowers prime emerging brands and manufacturers with a deep understanding of market trends and customer behavior to produce high-quality products to meet the demands of members. The company also developed several private labels in the mass consumption field, which are sold on its own platform as well as offered and sold through external channels. It operates in the PRC, and substantially all the Group's revenue is derived from within the PRC.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: